PSNL
PersonalisDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
If Personalis secures multiple recurring contracts and demonstrates improving gross margins, revenue growth could justify premium valuation and a move above $1.30 (driven by multiple expansion and improved cash metrics).
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +40.8.
What can break
Continued weak revenue, high cash burn, or an unfavorable financing would compress equity value toward or below $0.45; biotech/diagnostics microcaps often trade near liquidation or distressed levels during equity raises.
Momentum
94
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.90 · Bull $1.30 · Bear $0.45
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-26 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $11.57
Why
Momentum94 · Δ7d +40.8
Value41 · Δ7d +0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
94
34% active weight
Current posture
7d trendImproving
Δ7d
+40.8
Δ21d
+87.2
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
0
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade D. Momentum 93.8 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$1.17B
Beta
1.99
Shares Out
88.8M
P/E (TTM) · Derived
-14.4
P/S (TTM)
10.31
P/FCF (TTM) · Derived
-16.75
Rev YoY
-43.6%
EPS YoY
+61.9%
Gross Margin
+26.7%
Op Margin
-117.1%
Net Debt
-$183.24M
Current Ratio
4.82
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology